Senti Biosciences Holdings, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies using proprietary synthetic biology and gene circuit technologies. Its gene circuits are designed to program therapeutic cells to detect disease signals, respond to multiple targets, and spare healthy… From the company’s description.
In fiscal 2025, Senti Biosciences Holdings, Inc. reported revenue of $0.02M and a net loss of $61.44M. Operations used $43.44M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Senti Biosciences Holdings, Inc. does
In the company’s own words
Senti Biosciences, Inc. (Nasdaq: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies using proprietary synthetic biology and gene circuit technologies. Its gene circuits are designed to program therapeutic cells to detect disease signals, respond to multiple targets, and spare healthy cells. The company’s lead candidate, SENTI-202, is an off-the-shelf natural killer cell therapy being evaluated in a Phase 1 trial for relapsed or refractory blood cancers, including acute myeloid leukemia. Its pipeline also includes preclinical solid-tumor cell therapy programs and a collaboration with BlueRock Therapeutics on regenerative medicine cell therapies. Senti’s gene circuit platform is designed for potential use with cell types and modalities including NK cells, T cells, stem cells, viral gene therapy and mRNA. The company sold its manufacturing assets and facility to GeneFab in 2023 and uses GeneFab for clinical manufacturing services. Senti focuses its internal pipeline on oncology while pursuing partnerships for other applications. Its website is www.sentibio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1854270
- SIC
- 2836
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Senti Biosciences Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Senti Biosciences Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Senti Biosciences Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Senti Biosciences Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Senti Biosciences Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”